Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 25, 2007. The report serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding insider trading activity rather than a financial performance report.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a specific transaction by executive John Clarke:
- Option Exercise: On September 24, 2007, Clarke exercised options over 19,664 Ordinary shares granted on October 30, 1997, under the SmithKline Beecham Employee Share Option Plan 1991 at a price of GBP 12.28 per share.
- Share Sale: On the same date, Clarke sold 19,664 Ordinary shares at a price of GBP 13.26 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. It is strictly a compliance notification of the aforementioned share transaction.
Investor Verification Points
- Verify the total number of shares held by John Clarke post-transaction in subsequent filings.
- Confirm the pricing details (GBP 12.28 exercise price vs. GBP 13.26 sale price) against market data for September 24, 2007.
- Note that this filing does not reflect the company's broader financial performance for the period.